- Trials with a EudraCT protocol (609)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
609 result(s) found for: Blood pH.
Displaying page 8 of 31.
| EudraCT Number: 2015-003736-13 | Sponsor Protocol Number: CCTL019B2205J | Start Date*: 2017-09-29 |
| Sponsor Name:Novartis Pharmaceuticals | ||
| Full Title: A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia | ||
| Medical condition: Paediatric patients with B-cell acute lymphoblastic leukaemia and lymphoma who are refractory, relapsed to prior treatments | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2005-005040-85 | Sponsor Protocol Number: HaHes | Start Date*: 2006-03-17 |
| Sponsor Name:Department of Anesthesia, Div. of Cardiothoracic and Vascular Anesthesia, Medical University Vienna | ||
| Full Title: Comparison of Albumin 5%, Hydroxyethyl Starch 130/0.4 (6%) and Ringer Lactate for volume replacement during cardiac surgery | ||
| Medical condition: Intensive care patients after cardiac surgery requiring volume therapy | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-000881-35 | Sponsor Protocol Number: CLBH589B2202 | Start Date*: 2007-01-11 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors | |||||||||||||
| Medical condition: Adult patients with chronic phase Ph+ CML whose disease is resistant following treatment with at least two BCR-ABL tyrosine kinase inhibitors (i.e. imitinib, nilotinib, or dasatinib). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) BE (Completed) NL (Completed) FR (Completed) GB (Prematurely Ended) DE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-002203-15 | Sponsor Protocol Number: PregMet2 | Start Date*: 2012-08-08 | |||||||||||
| Sponsor Name:NTNU, Norwegian University of Science and Technology | |||||||||||||
| Full Title: Metformin treatment of pregnant PCOS women and prevention of late miscarriages and preterm birth The PregMet 2 Study | |||||||||||||
| Medical condition: Poly Cystic Ovarial Syndrome (PCOS) in pregnant women. PCOS should be diagnosed according to the Rotterdam Consensus criterias: - at least 2 out of 3 criterias 1.PCO in at least one ovary 2.Olig... | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: NO (Completed) SE (Completed) IS (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-003836-77 | Sponsor Protocol Number: OCTO-003 | Start Date*: 2008-12-09 |
| Sponsor Name:University of Oxford | ||
| Full Title: AspECT - A phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia & oesophagitis. | ||
| Medical condition: Barrett's Metaplasia | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-005513-18 | Sponsor Protocol Number: FARM6NJ3TZ | Start Date*: 2007-10-04 | |||||||||||
| Sponsor Name:OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA | |||||||||||||
| Full Title: Double blind randomized controlled study on the benefit-risk profile of in the treatment of at term or late preterm newborn infants with severe respiratory disorders and pulmonary hypertension | |||||||||||||
| Medical condition: treatment of at term or late preterm newborn infants with severe respiratory disorders and pulmonary hypertension | |||||||||||||
|
|||||||||||||
| Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-005681-13 | Sponsor Protocol Number: CLCI699A2206 | Start Date*: 2008-03-26 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A pilot, single-blind, forced-titration study to assess the hemodynamic and hormonal effects, safety and tolerability of the aldosterone synthase inhibitor LCI699 in patients with primary hyperaldo... | |||||||||||||
| Medical condition: hypertension artérielle par hyperaldostéronisme primaire | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-002059-40 | Sponsor Protocol Number: ECT-LANS-IL2 | Start Date*: 2012-06-28 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
| Full Title: Potentiating clinical and immunological effects of chemotherapy by neutralizing acidic pH at tumor site: a phase II randomized study in melanoma patients | |||||||||||||
| Medical condition: Metastatic Cutaneous and Subcutaneous Melanoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-000383-18 | Sponsor Protocol Number: LAL1913 | Start Date*: 2014-05-20 |
| Sponsor Name:G.I.M.EM.A. Gruppo Italiano Malattie EMatologiche dell'Adulto | ||
| Full Title: National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented... | ||
| Medical condition: National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: IT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-003517-17 | Sponsor Protocol Number: ALL2518 | Start Date*: 2019-09-26 | |||||||||||
| Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | |||||||||||||
| Full Title: Asparaginase Activity Monitoring (AAM) in adult patients with Acute Lymphoblastic Leukemia (ALL). | |||||||||||||
| Medical condition: Adult patients, aged between 18 and 65, diagnosed with Acute Ph Lymphoblastic Leukemia negative (LAL Ph-) untreated, with a favorable impact on the prognosis. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-006441-10 | Sponsor Protocol Number: 116-02 | Start Date*: 2009-06-03 |
| Sponsor Name:SCIPHARM SáRL | ||
| Full Title: A double blind controlled clinical study to investigate the efficacy and tolerability of subcutaneous Treprostinil sodium in patients with severe non-operable Chronic Thromboembolic Pulmonary Hyper... | ||
| Medical condition: Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) CZ (Completed) SK (Completed) DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-003423-21 | Sponsor Protocol Number: IK-7002-COPD-006 | Start Date*: 2014-09-29 | |||||||||||||||||||||||||||||||
| Sponsor Name:Bellerophon Pulse Technologies LLC | |||||||||||||||||||||||||||||||||
| Full Title: An Exploratory, Two-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects with World Health Organization (WHO) Group... | |||||||||||||||||||||||||||||||||
| Medical condition: Part 1: Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) Part 2: Pulmonary Hypertension (PH) Associated with Idiopathic pulmonary fibrosis (IPF) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-017594-37 | Sponsor Protocol Number: CVAL489K2305 | Start Date*: 2011-06-29 |
| Sponsor Name:Novartis Pharma Services AG | ||
| Full Title: A multicenter, open-label 18 month study to evaluate the long-term safety and tolerability of valsartan in children 6 to 17 years of age with hypertension and with or without chronic kidney disease. | ||
| Medical condition: Hypertension. | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Completed) FI (Completed) PL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-004119-30 | Sponsor Protocol Number: IP-AVV2019 | Start Date*: 2020-01-08 |
| Sponsor Name:Instituto Palacios | ||
| Full Title: EVALUATION OF THE ACCEPTABILITY AND EFFICACY OF 10 MICROGRAMS OF ESTRADIOL VAGINAL TABLETS VS PROMESTRIENE VAGINAL CREAM | ||
| Medical condition: VULVOVAGINAL ATROPHY | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-001005-41 | Sponsor Protocol Number: fluresstudy | Start Date*: 2014-12-10 |
| Sponsor Name:Ghent University Hospital | ||
| Full Title: Evaluation of FLuid REsuscitation with Sterofundin ® ISO (Ringerfundin), Plasma-Lyte® or NaCl 0.9%. (FluReS study) | ||
| Medical condition: hypovolemia-->need for fluid therapy | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-003912-28 | Sponsor Protocol Number: ALL2620 | Start Date*: 2021-01-28 | ||||||||||||||||
| Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | ||||||||||||||||||
| Full Title: Ponatinib for the management of minimal residual disease (MRD) and hematologic relapse in adult Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients. | ||||||||||||||||||
| Medical condition: Ph+ Acute Lymphoblastic Leukemia | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2014-004854-33 | Sponsor Protocol Number: 03-AnIt-14/UKM14_0066 | Start Date*: 2016-02-05 | ||||||||||||||||
| Sponsor Name:University Hospital Muenster | ||||||||||||||||||
| Full Title: Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH-Trial). | ||||||||||||||||||
| Medical condition: Critically ill patients with acute kidney injury | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2011-004823-11 | Sponsor Protocol Number: remifentanil2011 | Start Date*: 2012-08-03 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI | |||||||||||||
| Full Title: Randomized prospective multicenter study on remifentanil analgesic efficacy in labor: intermittent intravenous infusion administration vs continuous intravenous infusion | |||||||||||||
| Medical condition: women during labor | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-002982-33 | Sponsor Protocol Number: 2020-PDNO-002 | Start Date*: 2021-03-02 | |||||||||||
| Sponsor Name:Attgeno AB | |||||||||||||
| Full Title: An open-label, multicenter study to evaluate the efficacy, safety and tolerability of PDNO (nitrosooxypropanol) infusion in COVID-19 patients with acute pulmonary hypertension | |||||||||||||
| Medical condition: Acute pulmonary hypertension during COVID-19 infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-004613-24 | Sponsor Protocol Number: 01 | Start Date*: 2016-05-30 |
| Sponsor Name:Radboudumc | ||
| Full Title: Hit hard and early. The effect of high dose methylprednisolon on nailfold capillary changes and biomarkers in early SSc: a 12-week randomized double-blind placebo-controlled trial. | ||
| Medical condition: (very early) systemic sclerosis | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) BE (Completed) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.